On Thursday, Shares of Cisco Systems, Inc. (NASDAQ:CSCO), lost -1.65% to $28.61.
Cisco Systems, declared the new executive leadership team that incoming CEO Chuck Robbins has chosen to lead the organization into the next phase of its growth and success. The new team balances continuity in key positions with the elevation of the next generation of Cisco leaders from within the company, and world-class talent from outside of Cisco.
“The opportunity Cisco has to lead our customers into the digital age is incredible. The momentum we have in our business is undeniable. Our strategy is working, and with the leadership team I’m announcing recently, I’m extremely confident we will move even faster, innovate like never before, and pull away from the competition,” said Chuck Robbins, incoming Cisco CEO. “This is a remarkable team, with a diverse set of experiences, expertise and backgrounds to accelerate our innovation and execution, simplify how we do business, drive operational rigor in all we do, and inspire our amazing employees to be the best that they can be.”
Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking products and services related to the communications and information technology industry worldwide. It provides switching products, counting fixed-configuration and modular switches, and storage products that provide connectivity to end users, workstations, IP phones, wireless access points, and servers.
Shares of Groupon, Inc. (NASDAQ:GRPN), declined -2.36% to $6.01, during its last trading session.
Blue Calypso, Inc. (BCYP), developer of patented mobile consumer shopping engagement solutions for retailers and product manufacturers, recently declared the Court has reset a Claim Construction Hearing, or “Markman hearing” for July 8, 2015 in the Eastern District of Texas for Blue Calypso’s patent infringement lawsuits against Groupon (GRPN), Foursquare, Yelp (YELP) and IZEA (IZEA). The hearing had been planned for Jun 29, 2015. Judge Rodney Gilstrap will preside.
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
At the end of Thursday’s trade, Shares of Windstream Holdings, Inc. (NASDAQ:WIN), lost -4.10% to $7.72, hitting its lowest level.
Bob Gunderman, chief financial officer of Windstream Holdings, will speak at 4:25 p.m. CDT on Thursday, June 11, at the Barclays High Yield Bond & Syndicated Loan Conference in Colorado.
Windstream Holdings, Inc. provides communications and technology solutions in the United States. It offers managed services and cloud computing services to businesses, in addition to broadband, voice, and video services to consumers primarily in rural markets.
Finally, DARA BioSciences, Inc (NASDAQ:DARA), ended its last trade with 22.54% surge, and closed at $0.99.
DARA BioSciences, declared that it has signed a Merger Agreement with Midatech Pharma PLC (MTPH.L), an international specialty pharmaceutical company located in Oxford, UK with a diversified portfolio of high-value products in development.
DARA has reached a projected acquisition agreement with Midatech whereby each share of DARA will be converted into the right to receive (i) 0.272 Ordinary Shares of Midatech, subject to certain adjustments described in more detail below, and (ii) one Contingent Value Right (“CVR”). All Midatech Ordinary Shares will be delivered to the holders of DARA Common Stock in the form of American Depositary Receipts (“ADRs”). Based on the current price of Midatech, each DARA share will be converted into ADRs with a value equivalent to about $1.20 per DARA share. The ADRs will be listed on NASDAQ. Current DARA stockholders are predictable to own about 16% of Midatech after the closing of the transaction. Each CVR will represent the right to additional contingent cash payments in the event that certain sales milestones with respect to DARA’s products Gelclair® and Oravig® are met. A maximum aggregate value of $5.7 million in cash may become due and payable to the CVR holders in 2017 and 2018 upon attainment of the defined sales thresholds in 2016 and 2017, respectively.
DARA BioSciences, Inc., a specialty pharmaceutical company, focuses on commercialization of oncology treatment and supportive care pharmaceutical products in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
